Loading…
Flagstaff Federal Reversion Relief Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Flagstaff Federal Reversion Relief Act This bill releases any land (including the parcel of land in Flagstaff, Arizona, that is owned by Win Oil Co., Inc.,) that is subject to a federal reversionary interest pursuant to the Act of July 27, 1866, from any longer being subject to that interest. (That Act granted lands to aid in the construction of a railroad and telegraph line extending from Missouri and Arkansas to the West Coast.)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2022 · fourth_quarter · Health Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and Proposals related to drug pricing, including House and Senate draft bills Discussions on value-based contracting H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors; E.O. 13937, Access to Affordable Life-Saving Medications; E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients; E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen; E.O. 13947, 13948, Lowering Drug Prices by Putting America First; E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States; Issues related to plasma derived therapies; The Prescription Drug User Fee Act reauthorization Inflation Reduction Act
Read twice and referred to the Committee on Energy and Natural Resources.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and Proposals related to drug pricing, including House and Senate draft bills Issues related to the use of plasma therapies in COVID-19 patient; Discussions on value-based contracting H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors; E.O. 13937, Access to Affordable Life-Saving Medications; E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients; E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen; E.O. 13947, 13948, Lowering Drug Prices by Putting America First; E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States; Issues related to plasma derived therapies; The Prescription Drug User Fee Act reauthorization Inflation Reduction Act
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and Proposals related to drug pricing, including House and Senate draft bills Issues related to the use of plasma therapies in COVID-19 patient; Discussions on value-based contracting H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors; E.O. 13937, Access to Affordable Life-Saving Medications; E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients; E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen; E.O. 13947, 13948, Lowering Drug Prices by Putting America First; E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States; HR 5376, the Build Back Better Act Issues related to plasma derived therapies; The Prescription Drug User Fee Act reauthorization
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and Proposals related to drug pricing, including House and Senate draft bills Issues related to the use of plasma therapies in COVID-19 patient; Discussions on value-based contracting H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors; E.O. 13937, Access to Affordable Life-Saving Medications; E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients; E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen; E.O. 13947, 13948, Lowering Drug Prices by Putting America First; E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States; HR 5376, the Build Back Better Act Issues related to plasma derived therapies; The Prescription Drug User Fee Act reauthorization
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Real Estate/Land Use/Conservation
support for H.R. 402/S. 883, the Flagstaff Federal Reversion Relief Act, that would remove the federal reversionary interest on former railroad property.
Client expense: Not reported · Firm income: $10,000
Government targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Real Estate/Land Use/Conservation
support for H.R. 402/S. 883, the Flagstaff Federal Reversion Relief Act, that would remove the federal reversionary interest on former railroad property.
Client expense: Not reported · Firm income: $10,000
Government targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Real Estate/Land Use/Conservation
support for H.R. 402/S. 883, the Flagstaff Federal Reversion Relief Act, that would remove the federal reversionary interest on former railroad property.
Client expense: Not reported · Firm income: $20,000
Government targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE
2019 · second_quarter · Energy/Nuclear
Meetings and education on matters related to offshore oil and gas legislation generally, and specifically legislation, including S. 883, that would permit oil and gas revenue sharing with states and coastal political subdivisions of state.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · second_quarter · Real Estate/Land Use/Conservation
support for H.R. 402/S. 883, the Flagstaff Federal Reversion Relief Act, that would remove the federal reversionary interest on former railroad property.
Client expense: Not reported · Firm income: $20,000
Government targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, SENATE
2019 · first_quarter · Energy/Nuclear
Meetings and education on matters related to offshore oil and gas legislation generally, and specifically legislation, including S. 883, that would permit oil and gas revenue sharing with states and coastal political subdivisions of state.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · first_quarter · Real Estate/Land Use/Conservation
support for H.R. 402/S. 883, the Flagstaff Federal Reversion Relief Act, that would remove the federal reversionary interest on former railroad property.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE